MTS Medical

dermagold - first shockwave therapy system approved for skin lesions

MTS Europe GmbH and its partner, Tissue Regeneration Technologies, LLC. (TRT), are pioneers in the field of tissue regeneration. This partnership enables us to reach new milestones in our exploration of novel treatment methods in the field of dermatology. The Dermagold revolutionizes the treatment of chronic wounds and skin lesions by utilizing the biological effect of shock waves. The full potential of shock wave therapy is to date unknown, but MTS and TRT are on the cutting edge of research and development in this exciting field.

News

Meet us at :

Antibes, 05-07 June 2008
11th International Congress of the ISMST

Baden-Baden, 01-04 May 2008
56. Jahrestagung der Vereinigung Süddeutscher Orthopäden e.V.

Dubai, January 2008
MTS presents groundbreaking therapy possibility for diabetic foot syndrome

Dubai, 28-31 January 2008
Arab Health 2008 - German Pavilion, booth no. ZB43

Düsseldorf, 14-17 November 2007
Medica - hall 16, booth E41

Konstanz, November 2007
Find out more about orthowave100

Berlin, October 2007
orthowave100 - MTS proudly presents its latest device at "Deutscher Kongress für Orthopädie und Unfallchirurgie"

Berlin, 24-27 October 2007
Deutscher Kongress für Orthopädie und Unfallchirurgie

Milan, 27-29 September
Congresso Nazionale S.I.T.O.D.

Toronto, 6-9 June 2007 10th International Congress of ISMST

Vienna, 16-20 May 2007 16th EADV Congress

ATLANTA, May 2006
Siemens Medical Solutions and TRT Partner to unveil Lithogold at AUA 2006

KONSTANZ, April 2006
Dermagold - first device approved for skin lesions in Europe

VIENNA, September 2005
Skin Lesions Report